Related Experiment Video

Updated: Jun 20, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

Issues in the design and interpretation of antifungal drug trials in the critically ill

Luis Ostrosky-Zeichner1

  • 1Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas, USA. Luis.Ostrosky-Zeichner@uth.tmc.edu

Current Opinion in Infectious Diseases
|September 4, 2009
PubMed
Abstract

Insights

Antifungal clinical trials often exclude critically ill patients. While data is limited, preventive and early treatment strategies are recommended for select cases in critical care settings.

Area of Science:

  • Critical care medicine
  • Infectious diseases
  • Clinical pharmacology

Background:

  • Invasive fungal infections (IFIs), including candidiasis and aspergillosis, pose a significant threat in critical care.
  • Critically ill patients are often underrepresented in antifungal clinical trials.

Purpose of the Study:

  • To review clinical trials of antifungals in critically ill patients.
  • To examine methodological challenges in antifungal research for this population.
  • To discuss the implications for clinical practice and future research.

Main Methods:

  • Systematic review of published clinical trials.
  • Analysis of trial inclusion criteria and patient demographics.
  • Evaluation of antifungal treatment strategies in critical care.

Main Results:

  • Historically, critically ill patients have been a small fraction of trial participants.
  • Recent trials show a growing focus on specific antifungal approaches for this group.
  • New management strategies like prophylaxis and empirical therapy are emerging due to high mortality and diagnostic challenges.

Conclusions:

  • Limited data exist for preventive and early antifungal strategies in critically ill patients.
  • These strategies may be beneficial in highly selected patients and settings.
  • Extrapolation of data from general populations is often necessary but specific trials are warranted.

More Related Videos

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...